Mylan Nebivolol Hypertension Drug Patent Protection Expected Through 2015
Executive Summary
Mylan expects to secure patent protection for the hypertension drug nebivolol until 2015, six years after the composition of matter patent expires, President and Chief Operating Officer Richard Moldin told analysts.
You may also be interested in...
Mylan Places Big Bet On Antihypertensives: $4 Bil. Deal For King
Mylan's proposed acquisition of King is a big move by the generic company to carve out a leading position in the branded antihypertensive market
Mylan Places Big Bet On Antihypertensives: $4 Bil. Deal For King
Mylan's proposed acquisition of King is a big move by the generic company to carve out a leading position in the branded antihypertensive market
Roche Accutane Prescriber Registry Added To Pregnancy Prevention Program
Accutane prescribers must register with Roche to receive "qualification stickers" under the company's updated pregnancy prevention program